Triparna Sen/X
Apr 3, 2025, 17:54
Triparna Sen: Sen Lab Receives Third NIH/NCI R01 to Advance KRAS Co-mutant NSCLC Research
Triparna Sen, Associate Professor at Icahn School of Medicine at Mount Sinai, shared on X:
“Exciting News from the Sen Lab!
We are honored to receive our third NIH/NCI R01 to advance our research in KRAS co-mutant non-small cell lung cancer (NSCLC) – a disease with limited treatment options and a critical need for novel therapies.
With this funding, we will define the molecular and immune features driving disease progression and treatment resistance and identify novel therapeutic strategies.
This work would not be possible without the dedication of my team and the support of our collaborators. Research funding is essential to translating discoveries into new treatments and improving the lives of patients with lung cancer.”
See other posts by Triparna Sen on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 3, 2025, 17:06
Apr 3, 2025, 16:56
Apr 3, 2025, 16:37
Apr 3, 2025, 16:04
Apr 3, 2025, 15:12